Active, not recruitingNCT03133923Updated Oct 10, 2023

Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants

A Phase 2 interventional study of ≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old) and ≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old) in Epidemic Parotitis,Mumps, sponsored by Institute of Medical Biology, Chinese Academy of Medical Sciences. Active, not recruiting at 1 site in China. Open to participants aged 8 Months to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-10.

Sponsored by Institute of Medical Biology, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Prevention

Phase: Phase 2
Study type: Interventional
Enrollment: 1,080
Allocation: Randomized
Ages: 8 Months to 24 Months
Sex: All

Study summary

Mumps is an acute infectious respiratory disease caused by the mumps virus (MuV), which occurs mainly in children and adolescents. Its main clinical symptoms were parotid gland suppurative swelling and pain with fever. The pathological changes and harm caused by mumps was not only confined to the parotid gland, on the contrary, the social harm caused by serious complications cannot be ignored. As mumps is a vaccine-preventable infectious disease, vaccination is a fundamental strategy for controlling mumps. So far, there are 13 genotypes of MuV. Based on the analysis of molecular epidemiology, the main epidemic strain of MuV in China was the F genotype. The commonly used vaccine strains represented only a small number of known genotypes, e.g. Jeryl-Lynn (JL) and Rubini strains, which belong to type A, Urabe strain belongs to type B, and L-Zagreb strains belongs to type D. Virus seed of Live Attenuated Mumps Vaccine (Human diploid cell) developed by the institute was SP-A strain, which was the first separation and preparation of the attenuated mumps viruses in China. SP-A belongs to F genotype, which was the domestic epidemic genotype. In addition, the cell substrate prepared for vaccine was human diploid cell (KMB-17 strain), which is much safer to use. The preliminary test results showed that the vaccine possessed good immunogenicity and good antigenic cross-reactivity. The application of this vaccine will provide more effective means to prevent and control of mumps epidemic.

Read the detailed description

In order to evaluation the safety and immunogenicity of different doses Live Attenuated Mumps Vaccine (Human diploid cell).The study will Determine the optimal dose of vaccine and provide the clinical trail basis for the phase Ⅲ trail design.

Primary objective:

After single dose immunization of low dose(≥3.0but\<3.5lgCCID50)、high dose （≥4.5lgCCID50）Live Attenuated Mumps Vaccine (Human Diploid Cell) in Chinese healthy Infants volunteer aged from 8 to 24 months old.the study will evaluate the standardized positive rate of neutralizing antibody and the GMT of the hemagglutination inhibition antibody and neutralizing antibody,proposing the immune reference dose for phase III clinical trials.

Secondary objective： Evaluate the safety of low dose(≥3.0but\<3.5lgCCID50)、high dose （≥4.5lgCCID50）Live Attenuated Mumps Vaccine (Human Diploid Cell) in Chinese healthy Infants volunteer aged from 8 to 24 months old.

Conditions studied

Epidemic Parotitis,Mumps

Browse trials for

Mumps 46

Keywords

Attenuated Mumps Vaccine(F-genotype，Human Diploid Cell, KMB-17), safety, immunogenecity

Who can participate

Ages eligible: 8 Months to 24 Months
Sexes eligible: All
Accepts healthy volunteers: Yes

Inclusion criteria

Healthy males and females (from 8 months to 24 months old) as determined by medical history, physical examination, laboratory examination and clinical judgment of the investigator.
Provided legal identification for the sake of recruitment.
Without the routine corticosteroids of vaccination .
Never has gone down with mumps or taken a vaccine contain mumps.
parent(s)/legal guardian(s) are able to understand and sign informed consents and be able to read a thermometer and dividing ruler .At the same time,the parent(s)/legal guardian(s)should have the ability and objective to comply with the requirements of the protocol.
Participants or guardians are able to attend all planned clinical appointment and obey and follow all study instructions; can persist for a 1-month visit and receive blood sample and throat swab collection according to program requirements.
Axillary temperature ≤37℃.

Exclusion criteria

Exclusion Criteria:

Subject who has a medical history of Mumps or taken a vaccine contain mumps.
Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
Convulsant,encephalopathy,psychosis or family histoty of epileptics.
Clinical diagnosis of coagulopathy (such as clotting factor deficiency, coagulation disorders, platelet abnormalities), significant bruising or blood clotting disorder,it will couse the contraindication of subcutaneous injection
Any prior administration of attenuated live vaccine in last 15 days;Any prior administration of subunit or inactivated vaccines in last 7 days
Any prior administration of other research medicines in last 30 days.
Any prior administration of blood products(immunoglobulin etc.) in last 1 month;Any prior administration of immunodepressant ，cytotoxic drugs or corticosteroids in last 6 months(except the corticosteroids spray can treat irritability rhinitis orcorticosteroids to cure noncomplication acute dermatitis ).
Any confirmed or suspected autoimmune disease or immune deficiency diseases(like favism or other diseases etc. ), including human immunodeficiency virus (HIV) infection.
Suffering from congenital deformity or serious chronic disease(congenital heart disease，Down's syndrome,diabetes,sickle cell anemia,nervous illness,cardiocardiopathy,hypertension,bronchitis,pneumonia,asthma,infectious skin diseases)
Acute or chronic infectious disease,active infectious;Laboratory test show Routine blood abnormal or hepatorenal dysfunction.
Malignant disease(like cancer)，heredopathia or other disease that will cuase eccyliosis.The spleen or other important organ has been removed for any reason.
Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives.

Study design

Phase: Phase 2
Primary purpose: Prevention
Allocation: Randomized
Intervention model: Parallel assignment
Masking: Triple (Participant, Care provider, Investigator)
Enrollment: 1,080 participants (estimated)

Study arms

Experimental
Attenuated Mumps vaccine (KMB-17), low
Biological/Vaccine: ≥3.0logCCID50/ml but \<3.5 logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[ ≥3.0logCCID50/ml but \<3.5 logCCID50/ml\] in 360 infants (8-24 months old) on 0 day
Biological: ≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
Experimental
Attenuated Mumps vaccine (KMB-17), high
Biological/Vaccine: ≥4.5logCCID50/ml Attenuated Mumps vaccine (KMB-17)\[≥4.5 logCCID50/ml\] in 360 infants (8-24 months old) on 0 day
Biological: ≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
Active comparator
Measles and Mumps Combined Vaccine，Live
manufacturer：Shanghai Institute of Biological Products Co., Ltd. (SIBP ) Measles and Mumps Combined Vaccine，Live in 360 infants in 360 infants (8-24 months old) on 0 day
Biological: Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)

Interventions

Biological≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
Biological≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)
≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
BiologicalMeasles and Mumps Combined Vaccine，Live(SIBP)( positive control)
Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day

What researchers measure

Primary outcomes

Positive conversion rate of Muv hemagglutination inhibition antibody of different single dose of Muv Vaccine
To compared the positive conversion rate of Muv hemagglutination inhibition antibody after vaccinate 3 diffirent group (low dose:≥3.0logCCID50/ml but \<3.5logCCID50/ml,high dose：≥4.5logCCID50/ml,active comparator :shanghai institute of Biological Products Co,Ltd's measles and Mumps Combined Vaccine.live)
Time frame: the 0 days（before vaccination） and 28 day after the vaccination
Positive conversion rate of Muv neutralization antibody of different single dose of Muv Vaccine
To compared the positive conversion rate of Muv neutralization antibody after vaccinate 3 diffirent group (low dose:≥3.0logCCID50/ml but \<3.5logCCID50/ml,high dose：≥4.5logCCID50/ml,active comparator :shanghai institute of Biological Products Co,Ltd's measles and Mumps Combined Vaccine.live)
Time frame: the 0 days（before vaccination） and 28 day after the vaccination

Secondary outcomes

The GMT of the hemagglutination inhibition antibody and neutralizing antibody
evaluate the GMT of the hemagglutination inhibition antibody and neutralizing antibody in serum after the subjects get injected different dose of vaccine
Time frame: the 0 days（before vaccination） and the 28 day after the vaccination
The GMT of the neutralizing antibody
evaluate the GMT of the neutralizing antibody in serum after the subjects get injected different dose of vaccine
Time frame: the 0 days（before vaccination） and the 28 day after the vaccination
The incidence rate of ADR after vaccination
Study the incidence rate of ADR after vaccination
Time frame: within the first 28 days after the vaccination
viral shedding after the vaccination
Using the method of PCR to detection the viral shedding of Muv after the vaccination.
Time frame: the 0（before vaccination）,4,10 days after the vaccination

Study locations

1 site

Hubei Provincial Center for Disease Control and Prevention
Wuhan, Hubei 430079, China

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

Registry details

Key details

Study ID: NCT03133923
Lead sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences
Collaborators: Hubei Provincial Center for Disease Control and Prevention
Responsible party: Sponsor
First posted: Apr 28, 2017
Start date: May 20, 2017
Primary completion: Nov 10, 2017
Completion: Jul 1, 2024 (estimated)
Last update: Oct 10, 2023

Study contacts

Beifang Yang, PhD

principal investigator · Hubei Provincial Center for Disease Control and Prevention

Oversight

Data monitoring committee: Yes
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Mumps→

Other studies from this sponsor

Institute of Medical Biology, Chinese Academy of Medical Sciences

Start the discussion